阅读说明：本技术 反式1,3-二亚油精在制备治疗胃癌药物、健胃药物、保健品和食品中的应用 (Application of trans-1, 3-dilinolein in preparation of drugs for treating gastric cancer, drugs for invigorating stomach, health products and foods ) 是由 戴建业 金铮 马茹芸 朱燕宁 于 2021-01-09 设计创作，主要内容包括：本发明公开了反式1,3-二亚油精新的药物食品用途,即反式1,3-二亚油精在制备健胃药物中的应用以及在制备治疗胃癌的药物中的应用。细胞实验表明,反式1,3-二亚油精对于常氧和低氧条件下人胃粘膜上皮细胞系GES-1的增殖有促进作用,对于人胃癌细胞系HGC-27具有浓度依赖性杀伤作用且对低氧胃癌细胞具有更强杀伤作用。且在300μM及以上浓度时反式1,3-二亚油精明显杀伤胃癌细胞且低氧条件下效果更为显著,同时明显促进正常胃黏膜上皮细胞的增殖,可用于制备保护正常胃粘膜细胞、杀伤胃癌细胞的健胃抗癌药物,亦可用于制作具有健胃功效的保健品和功能性食品。(The invention discloses a novel medicinal food application of trans-1, 3-dilinolein, namely an application of the trans-1, 3-dilinolein in preparing a stomach-invigorating medicament and an application in preparing a medicament for treating gastric cancer. Cell experiments show that the trans-1, 3-dilinolein has a promoting effect on the proliferation of a human gastric mucosal epithelial cell line GES-1 under the conditions of normal oxygen and hypoxia, has a concentration-dependent killing effect on a human gastric cancer cell line HGC-27 and has a stronger killing effect on hypoxic gastric cancer cells. And the trans-1, 3-dilinolein obviously kills gastric cancer cells at the concentration of 300 mu M or more, has more obvious effect under the condition of hypoxia, simultaneously obviously promotes the proliferation of epithelial cells of normal gastric mucosa, can be used for preparing stomach-invigorating anticancer drugs for protecting normal gastric mucosa cells and killing gastric cancer cells, and can also be used for preparing health-care products and functional foods with the stomach-invigorating effect.)

1. The application of trans-1, 3-dilinolein in preparing a medicine for treating gastric cancer is disclosed, wherein the chemical structural formula of the trans-1, 3-dilinolein is as follows:

。

2. use according to claim 1, characterized in that: the trans-1, 3-dioledin is used as an active pharmaceutical ingredient of a medicament for treating gastric cancer;

preferably, the trans-1, 3-dioledin is used as the sole active pharmaceutical ingredient of a medicament for the treatment of gastric cancer.

3. The application of trans-1, 3-dilinolein in preparing stomach-invigorating drugs, wherein the chemical structural formula of the trans-1, 3-dilinolein is as follows:

；

preferably, the trans-1, 3-dilinolein is used as an active pharmaceutical ingredient of a stomach invigorating medicament;

more preferably, said trans-1, 3-dilinolein is used as the sole active pharmaceutical ingredient of a stomachic drug.

4. The application of the trans-1, 3-dilinolein in preparing the health care product with the stomach invigorating effect is characterized in that the chemical structural formula of the trans-1, 3-dilinolein is as follows:

；

preferably, the trans-1, 3-dilinolein is used as a stomach-invigorating active ingredient of a health care product;

more preferably, the trans-1, 3-dilinolein is used as the sole stomach-invigorating active ingredient of the health care product.

5. The application of trans-1, 3-dilinolein in preparing functional food with stomach invigorating effect is provided, wherein the chemical structural formula of the trans-1, 3-dilinolein is as follows:

。

6. application of trans-1, 3-dilinolein as food additive with stomach invigorating effect is provided.

7. An anti-gastric cancer drug is characterized in that: the anti-gastric cancer medicine comprises trans-1, 3-dilinolein as an active medicine component and one or more pharmaceutically acceptable auxiliary materials;

the chemical structural formula of the trans-1, 3-dilinolein is as follows:

；

preferably, the anti-gastric cancer drug is a drug having an activity of inhibiting gastric cancer cell proliferation in an normoxic and/or hypoxic environment.

8. A stomach invigorating medicine which is characterized in that: the stomach-invigorating medicine comprises trans-1, 3-dilinolein as an active medicine component and one or more pharmaceutically acceptable auxiliary materials;

the chemical structural formula of the trans-1, 3-dilinolein is as follows:

；

preferably, the stomach-invigorating drug is a drug having activity of promoting proliferation of epithelial cells of gastric mucosa in normoxic and/or hypoxic environment.

9. A stomach-invigorating health product is characterized in that: the stomach-invigorating health product comprises trans-1, 3-dilinolein as a stomach-invigorating active ingredient.

10. A functional food with stomach invigorating effect is characterized in that: the functional food comprises trans-1, 3-dilinolein with stomach invigorating activity.

Technical Field

The invention belongs to the field of medical food, and particularly relates to application of trans-1, 3-dilinolein in preparation of medicines for treating gastric cancer, stomachic medicines, stomachic health-care products and functional food.

Background

Cancer is always a big enemy of human beings, and according to the latest statistics of world health organization (http:// gco. iarc. fr/today), only 2018 years, 1800 ten thousand of cancer patients are worldwide, and the number of death people due to cancer exceeds 950 ten thousand; the number of cancer patients in China is 420 ten thousands, and the number of death patients is more than 280 thousands. Especially, the number of gastric cancer patients and deaths in China exceeds 40 percent of the number of liver cancer patients and deaths in the world. The early treatment of gastric cancer patients is mainly surgical treatment, and the five-year survival rate can reach more than 80%. Unfortunately, the early diagnosis rate of gastric cancer in our country is less than 10%, and more than 90% of patients are in the advanced stage when they are found. At this time, the gold period of radical operation is missed, and chemotherapy is mostly adopted. Many chemicals do not distinguish normal gastric mucosal epithelial cells from gastric cancer cells and kill them all. Therefore, the research and the discovery of the anticancer active molecules which can protect the epithelial cells of the normal gastric mucosa and kill the gastric cancer cells have great significance for developing the drugs with the spleen-strengthening anticancer activity and the health products.

[ 2-hydroxy-3- [ (9E, 12E) -octadeca-9, 12-dienoyl ] oxypropyl ] (9E, 12E) -octadeca-9, 12-dienoic acid ester, also known as trans-1, 3-dioleitin, has the following chemical formula:

CAS number: 372516-93-3, and no literature is available on reporting that the compound has stomach-invigorating and anti-gastric cancer activities.

Disclosure of Invention

The invention aims to provide a novel medicinal food application of trans-1, 3-dilinolein.

In order to achieve the purpose, the technical scheme adopted by the invention is as follows:

1. application of trans-1, 3-dilinolein in preparing medicine for treating gastric cancer.

2. Application of trans-1, 3-dilinolein in preparing stomach-invigorating medicine is provided.

3. Application of trans-1, 3-dilinolein in preparing health products with stomach invigorating effect.

4. Application of trans-1, 3-dilinolein in preparing functional food with stomach invigorating effect is provided.

5. Application of trans-1, 3-dilinolein as food additive with stomach invigorating effect is provided.

6. An anti-gastric cancer medicament comprises trans-1, 3-dilinolein as an active medicament component and one or more pharmaceutically acceptable auxiliary materials.

7. A stomachic medicine comprises trans-1, 3-dilinolein as an active medicine component and one or more pharmaceutically acceptable auxiliary materials.

8. A stomach-invigorating health product comprises trans-1, 3-dilinolein as a stomach-invigorating active ingredient.

9. A functional food with stomach invigorating effect comprises trans-1, 3-dilinolein with stomach invigorating activity.

Drawings

FIG. 1 is a nuclear magnetic spectrum of 1, 2-glycerol acetolactone.

FIG. 2 is a nuclear magnetic spectrum of (2, 2-dimethyl-1, 3-dioxolan-4-yl) -methyl (9E, 12E) -9, 12-octadecadienoic acid ester.

FIG. 3 is a nuclear magnetic spectrum of trans-1, 3-dioledin.

FIG. 4 shows the effect of trans-1, 3-dilinolein on normal gastric mucosal cells and gastric cancer cells of a human, wherein A is the stomach-invigorating effect of trans-1, 3-dilinolein on promoting proliferation of normal gastric mucosal epithelial cells of a human under normoxic conditions; b is the stomach invigorating function of trans-1, 3-dilinolein for promoting the proliferation of epithelial cells of normal gastric mucosa of human under the hypoxia condition; c is the anti-cancer effect of trans-1, 3-dilinolein for inhibiting the proliferation of human gastric cancer cells under the normoxic condition; d is the anti-cancer effect of trans-1, 3-dioledin in inhibiting the proliferation of human gastric cancer cells under the condition of hypoxia.

Detailed Description

The present invention will be described in further detail with reference to the following drawings and examples.

The trans-1, 3-dilinolein has the following chemical structural formula:

。

the invention provides application of trans-1, 3-dilinolein in preparation of a medicine for treating gastric cancer.

In some embodiments, the trans 1, 3-dioledin is used as an active pharmaceutical ingredient of a medicament for treating gastric cancer.

In some embodiments, the trans 1, 3-dioledin is the sole active pharmaceutical ingredient of a medicament for treating gastric cancer.

The invention also provides an anti-gastric cancer medicament, which comprises trans-1, 3-dilinolein serving as an active medicinal ingredient and one or more pharmaceutically acceptable auxiliary materials.

In some embodiments, the anti-gastric cancer drug is a drug having an activity of inhibiting proliferation of gastric cancer cells in an normoxic and/or hypoxic environment.

In some embodiments, the dosage form of the anti-gastric cancer drug can be a pharmaceutically acceptable dosage form such as tablets, granules, capsules and the like.

In some embodiments, the pharmaceutically acceptable excipients include fillers, binders, disintegrants, lubricants, glidants, flavoring agents, coloring agents, and the like.

The invention also provides application of the trans-1, 3-dilinolein in preparation of a stomach invigorating medicine.

In some embodiments, the trans 1, 3-dioledin is used as an active pharmaceutical ingredient of a stomachic drug.

In some embodiments, the trans 1, 3-dioledin is the sole active pharmaceutical ingredient of the stomachic drug.

The invention also provides a stomach-invigorating medicament which comprises trans-1, 3-dilinolein serving as an active medicinal ingredient and one or more pharmaceutically acceptable auxiliary materials.

In some embodiments, the stomach-invigorating drug is a drug having activity of promoting proliferation of gastric mucosal epithelial cells in normoxic and/or hypoxic environments.

In some embodiments, the stomach-invigorating drug may be in the form of a pharmaceutically acceptable dosage form such as a tablet, a granule, a capsule, and the like.

In some embodiments, the pharmaceutically acceptable excipients include fillers, binders, disintegrants, lubricants, glidants, flavoring agents, coloring agents, and the like.

Based on the good promotion effect on the proliferation of the normal human gastric mucosal epithelial cell line GES-1 under the normal oxygen and hypoxia conditions, the trans-1, 3-dilinolein can also be used for preparing health care products with the stomach invigorating effect, and the trans-1, 3-dilinolein is used as a food additive with the stomach invigorating effect to prepare functional foods with the stomach invigorating effect.

2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoate is a dihydroxy compound, and two hydroxyl groups are adjacent, and in order to selectively introduce octadeca-9, 12-diene into the terminal hydroxyl group, the present invention also provides a method for preparing trans-1, 3-dioleitin, which comprises:

under the action of 4-Dimethylaminopyridine (DMAP) and triethylamine, 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoic acid ester reacts with (9E, 12E) -9, 12-octadecadienoyl chloride to obtain the trans-1, 3-dioleylidene essence.

In some embodiments, 4-dimethylaminopyridine is used in an amount of 1-20% by mass of 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoate.

In some embodiments, 4-dimethylaminopyridine is used in an amount of 1%, 2%, 4%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, or any two of the range, such as 8-12%, by mass of 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoate.

In some embodiments, triethylamine is used in an amount of 0.5 to 5 times the mass of 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoate.

In some embodiments, triethylamine is used in an amount that is 0.5 times, 1 times, 1.5 times, 2 times, 2.5 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times, or any two of the above ranges, such as 1.5-2 times, the mass of 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoate.

In some embodiments, the molar ratio of 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoic acid ester to (9E, 12E) -9, 12-octadecadienoyl chloride is controlled to be 1:0.1 to 1: 10.

In some embodiments, the molar ratio of 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoic acid ester to (9E, 12E) -9, 12-octadecadienoyl chloride is 1:0.1, 1:0.5, 1:1, 1:1.5, 1:2, 1:3, 1:4, 1:6, 1:10, or a range of any two, such as 1:1 to 1: 2.

The reaction can be carried out in an inert solvent such as Dichloromethane (DCM).

The reaction is carried out in an ice bath, and the reaction time can be controlled to be 10-24 hours.

In some embodiments, the 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoate may be prepared by a method comprising:

(1) under the action of catalytic amount of acid, glycerol reacts with acetone to obtain 1, 2-glycerol acetolactone;

(2) under the action of 4-dimethylamino pyridine and dicyclohexyl carbodiimide (DCC), 1, 2-glycerol acetolactone reacts with trans-linoleic acid to obtain (2, 2-dimethyl-1, 3-dioxolan-4-yl) -methyl (9E, 12E) -9, 12-octadecadienoic acid ester;

(3) hydrolyzing (2, 2-dimethyl-1, 3-dioxolane-4-yl) -methyl (9E, 12E) -9, 12-octadecadienoic acid ester under the action of acid to obtain the 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoic acid ester.

In some embodiments, the acid of step (1) is selected from p-toluenesulfonic acid.

In some embodiments, the p-toluenesulfonic acid is used in an amount of 0.01 to 0.1% by mole of the glycerol.

In a preferred embodiment, p-toluenesulfonic acid is used in an amount of 0.05% by mole of glycerol.

In some embodiments, the reaction temperature of the glycerol and the acetone in the step (1) is controlled to be 50-100 ℃.

In a preferred embodiment, the temperature at which glycerol is reacted with acetone is controlled at 70 ℃.

In some embodiments, the 4-dimethylaminopyridine in step (2) is used in an amount of 1-10% by mass of the 1, 2-glyceryl acetolactone.

In a preferred embodiment, the amount of the 4-dimethylaminopyridine is 4-6% of the mass of the 1, 2-glycerol acetolactone.

In some embodiments, the dicyclohexylcarbodiimide used in step (2) is 1 to 5 times of the mass of the 1, 2-glycerol acetolactone.

In a preferred embodiment, the amount of dicyclohexylcarbodiimide used is 3-4 times of the mass of 1, 2-glyceryl acetolactone.

In some embodiments, the acid of step (3) is selected from acetic acid.

In a preferred embodiment, the temperature of the hydrolysis in the step (3) is controlled to be 40-60 ℃.

In some embodiments, the (9E, 12E) -9, 12-octadecadienoyl chloride may be prepared by:

under the action of Dimethylformamide (DMF), the trans-linoleic acid reacts with thionyl chloride to obtain (9E, 12E) -9, 12-octadecadienoyl chloride.

In some embodiments, the trans linoleic acid is reacted with excess thionyl chloride.

In a preferred embodiment, the dosage of the thionyl chloride is 2-5 times of the molar weight of the trans-linoleic acid.

The chemical structure of trans-linoleic acid:。

example 1

The synthetic route of trans-1, 3-dioledin is as follows:

the specific process is as follows:

(1) synthesis of 1, 2-glyceryl acetolactone

Glycerol (40 mmol, 3.223 g) and p-toluenesulfonic acid (0.02 mmol)l, 0.004 g) was placed in a 100 ml round bottom flask, acetone (31.5 mmol, 1.83 g) was added to dissolve it, hexane (11 ml) was added at 70 ℃,1 ml of acetone was added every 12 hours, the reaction was carried out for 48 to 60 hours under the conditions, the reaction was detected by TLC, after completion of the reaction, the solvent was removed by rotary evaporation under reduced pressure, and then the compound 1, 2-glyceroacetolactone (chemical structural formula:）。

(2) synthesis of (2, 2-dimethyl-1, 3-dioxolan-4-yl) -methyl (9E, 12E) -9, 12-octadecadienoic acid ester

1, 2-Glycerol acetolactone (1.07 mmol, 0.141 g), trans-linoleic acid (1.07 mmol, 0.300 g) and DMAP (0.06 mmol, 0.007 g) were placed in a 50ml round bottom flask, dichloromethane (6 mL) was added and dissolved, DCC (2.14 mmol, 0.441 g) was dissolved in 4 mL dichloromethane, dropwise adding into a round-bottom flask containing 1, 2-glycerol acetolactone under ice bath (0 deg.C), reacting at room temperature overnight for TLC detection, suction filtering to remove insoluble solid after reaction, washing with petroleum ether for 3-5 times, collecting filtrate, vacuum rotary steaming, then separating and purifying by a silica gel column to obtain a compound (2, 2-dimethyl-1, 3-dioxolane-4-yl) -methyl (9E, 12E) -9, 12-octadecadienoic acid ester (chemical structural formula:）。

(3) synthesis of 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoic acid ester

Placing (2, 2-dimethyl-1, 3-dioxolane-4-yl) -methyl (9E, 12E) -9, 12-octadecadienoic acid ester (0.76 mmol, 0.301 g) in a 25 ml round-bottom flask, adding 2880 ul glacial acetic acid and 720 ul water to dissolve the (2, 2-dimethyl-1, 3-dioxolane-4-yl) -methyl (9E, 12E) -9, 12-octadecadienoic acid ester, heating and refluxing for 7-12 hours at 50 ℃, detecting the reaction by TLC, extracting with ethyl acetate for three times after the reaction is completed, washing the obtained organic phase twice with saturated NaCl solution and anhydrous Na₂SO₄Drying, collecting filtrate, performing rotary evaporation under reduced pressure, and separating and purifying by silica gel column to obtain 2, 3-dihydroxypropane compoundThe radical (9E, 12E) -9, 12-octadecadienoic acid ester.

(4) Synthesis of trans-1, 3-dilinolein

Trans-linoleic acid (0.423 mmol, 0.118 g), thionyl chloride (1.69 mmol, 0.201 g, 120 ul, 4eq) were placed in a 50ml round bottom flask, dissolved by adding 6 ml dichloromethane, and three drops of DMF were added. After the reaction is carried out for 12 hours, TLC detection reaction is carried out, the solvent is removed by rotary evaporation after the reaction is completed, 6 ml of dichloromethane is added for rotary evaporation for three times to remove the thionyl chloride, and a compound (9E, 12E) -9, 12-octadecadienoyl chloride (chemical structural formula:). This was dissolved in 2 ml of dichloromethane and charged into a 50ml reaction flask containing 2, 3-dihydroxypropyl (9E, 12E) -9, 12-octadecadienoic acid (0.282 mmol, 0.100 g), DMAP (10%, 10 mg) and triethylamine (1.805 mmol, 0.183 g, 248 ul, 6.4 eq) were added to 2-4 ml of dichloromethane and added dropwise to the 50ml reaction flask under ice bath (0 ℃). And (3) reacting for 12 hours, detecting by TLC, removing the solvent by rotary evaporation after the reaction is completed, and then separating and purifying by a silica gel column to obtain the compound trans-1, 3-dilinolein with the yield of 50%.

Example 2 cell model experiment of Trans-1, 3-Dilinolein

Cell culture

Human gastric cancer cell line HGC-27 cells, human gastric mucosal epithelial cell line GES-1 cells (from China center for type culture Collection (Wuhan, China)) 37 ℃, 5% CO₂Cultured in RPMI Medium Modified (Hyclone, SH 30809.01), Dulbecco's Modified Eagle's Medium-high glucose (Sigma, D6429), supplemented with 10% fetal bovine serum (Gibco,10270-106) and 1% penicillin-streptomycin (Gibco, 15140-122), respectively.

Cell activity assay

Cytotoxicity assay of trans-1, 3-dioleylidene sperm against HGC-27 cells. 5000 cells were plated in 96-well plates, and 100. mu.L of medium was added per well. After 12 hours from the attachment, 100. mu.L of a normal medium containing trans 1, 3-diolequin at various concentrations (0. mu. M, 50. mu. M, 100. mu. M, 200. mu. M, 300. mu. M, 400. mu. M, 500. mu. M) and preheated was administered per well, and cultured in 5% carbon dioxide, 37 ℃ ordinary oxygen and 1% oxygen incubators for 48 hours, respectively. The medium was aspirated from each well, serum-free medium was added to each well to prepare 60. mu.L of MTS (Promega) containing 1/6 original concentration, and the medium was incubated in a 5% carbon dioxide incubator at 37 ℃ under normal oxygen or 1% oxygen for 2 hours, and absorbance at 490nm was measured by a microplate reader (Thermo Scientific).

Cytotoxicity assay of trans-1, 3-dioleitin on GES-1 cells. 10000 cells were plated in 96-well plates and 100. mu.L of medium was added per well. After 12 hours of attachment, 100. mu.L of a normal medium containing trans-1, 3-dilinolein at various concentrations (0. mu. M, 6.25. mu. M, 12.5. mu. M, 25. mu. M, 50. mu. M, 100. mu. M, 200. mu. M, 400. mu. M, 800. mu. M, 1000. mu. M) was administered per well and was preheated, and cultured in 5% carbon dioxide, 37 ℃ ordinary oxygen and 1% oxygen incubators, respectively, for 48 hours. The medium was aspirated from each well, and serum-free medium was added to each well to prepare 60. mu.L of CCK8 (ABMole BioScience) containing 1/11 original concentration, and absorbance at 450nm was measured by a microplate reader (Thermo Scientific) in an incubator containing 5% carbon dioxide, 37 ℃ and either normal oxygen or 1% oxygen for 40 minutes.

Statistics of

Two sets of measurements were tested for statistical significance using EXCEL, a two-sided Student's t-test. P values <0.05 were considered statistically significant. All data are expressed as means ± standard deviation, unless otherwise indicated.

Results of the experiment

As shown in FIG. 4, trans-1, 3-dioledin has an effect of promoting the proliferation of human gastric mucosal epithelial cell line GES-1 under normoxic and hypoxic conditions in the range of 25. mu.M to 400. mu.M (FIGS. 4A-B). Trans-1, 3-dioleitin has concentration-dependent killing effect on human gastric cancer cell line HGC-27 and stronger killing effect on hypoxic gastric cancer cells (FIG. 4C-D). It is worth noting that at concentrations of 300 μ M and above, trans-1, 3-dilinolein significantly kills gastric cancer cells and has a more significant effect under hypoxic conditions, while significantly promoting proliferation of normal gastric mucosal epithelial cells. The above results suggest that trans-1, 3-dilinolein is a potentially excellent stomach-invigorating anticancer active ingredient that can protect normal gastric mucosal cells and kill gastric cancer cells.

Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.